SpineThera SALIENT Clinical Trial Results to Be Presented at Upcoming 22nd Annual ASRA Pain Medicine Meeting
PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection [TF-EI] for the management of sciatica pain) today announced that the submitted abstract,” Clinically Meaningful Radicular Leg Pain Management via Novel Dexamethasone Extended Release Microsuspension (SX600)- PH1/2 Results” has been accepted for presentation at the 22nd Annual Pain Medicine Meeting hosted by the American Society of Regional Anesthesia and Pain Medicine (ASRA).
“We are excited to share these important clinical study results with the global pain medicine community and engage in meaningful discussions with fellow professionals at the ASRA conference”
This achievement is a significant milestone in the field of pain medicine. The well renowned conference is one of the premier events of the year, gathering experts, practitioners, and researchers from around the world to exchange knowledge, share innovative research, and discuss the latest advancements in pain management.
This abstract was selected from a highly competitive pool of submissions highlighting groundbreaking research and advancements in pain medicine that have the potential to improve the lives of patients suffering from various pain conditions. SpineThera will be presenting their findings from the SALIENT Trial where clinically meaningful reduction in unilateral radicular leg pain with a favorable safety profile was demonstrated for SX600 compared with placebo.
The acceptance of this abstract underscores the dedication and expertise of the team at SpineThera. Chief Medical Officer, Dr. Lee Techner, will present the abstract at the conference. “We are excited to share these important clinical study results with the global pain medicine community and engage in meaningful discussions with fellow professionals at the ASRA conference” Dr. Techner said.
The ASRA 22nd Annual Pain Medicine Meeting will take place November 10-11, 2023, in New Orleans. Attendees are encouraged to join the presentation to learn more about this groundbreaking research and the potential impact it may have on the field of pain medicine.
SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its patented micro-suspension platform technology. SpineThera’s micro-suspension provides months long sustained release of the active pharmaceutical ingredient with superior injectability at ultra-high concentrations. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs.
SpineThera's flagship investigational drug product, SX600, is a groundbreaking dexamethasone acetate micro-suspension injection which has been meticulously engineered as a targeted, extended-release corticosteroid with the potential to demonstrate a substantially improved benefit-risk profile compared to current epidural steroid injections for radicular leg pain. SpineThera, Inc., is based in Medical Alley, Minnesota, the global epicenter of health innovation and care.
Jeff Missling, CEO